Healios K.K. (OTCMKTS:HLOSF – Get Free Report) is expected to be posting its results on Thursday, November 12th. Analysts expect the company to post earnings of ($0.0719) per share and revenue of $0.21 million for the quarter.
Healios K.K. Stock Performance
Healios K.K. stock opened at $1.80 on Wednesday. The firm has a 50-day moving average price of $1.80 and a 200-day moving average price of $2.00. Healios K.K. has a 12-month low of $1.80 and a 12-month high of $4.45.
About Healios K.K.
Healios K.K. is a Japanese biotechnology company focused on developing regenerative medicine and cell therapies. Its research draws on induced pluripotent stem cell (iPSC) technology and somatic stem cell platforms, with the goal of treating serious diseases that have limited treatment options. The company’s development programs have included HLCM051, a stem cell therapy investigated for conditions such as acute ischemic stroke and acute respiratory distress syndrome, as well as iPSC-based approaches for diseases including retinal disorders.
Read More
- Five stocks we like better than Healios K.K.
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
